List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2396705/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the United States of America, 2006, 103, 2257-2261.	3.3	5,220
2	miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13944-13949.	3.3	3,287
3	A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2005, 353, 1793-1801.	13.9	2,255
4	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15805-15810.	3.3	1,538
5	MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proceedings of the United States of America, 2004, 101, 11755-11760.	3.3	1,238
6	MiR-15a and miR-16-1 cluster functions in human leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5166-5171.	3.3	741
7	MicroRNA expression and function in cancer. Trends in Molecular Medicine, 2006, 12, 580-587.	3.5	699
8	Ultraconserved Regions Encoding ncRNAs Are Altered in Human Leukemias and Carcinomas. Cancer Cell, 2007, 12, 215-229.	7.7	681
9	Tcl1 Expression in Chronic Lymphocytic Leukemia Is Regulated by miR-29 and miR-181. Cancer Research, 2006, 66, 11590-11593.	0.4	568
10	MicroRNA fingerprints during human megakaryocytopoiesis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5078-5083.	3.3	403
11	Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet, The, 2003, 361, 1693-1699.	6.3	395
12	MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene, 2007, 26, 4148-4157.	2.6	351
13	Association of a MicroRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia. JAMA - Journal of the American Medical Association, 2011, 305, 59.	3.8	256
14	An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene, 2009, 28, 73-84.	2.6	230
15	In vivo telomere dynamics of human hematopoietic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 13782-13785.	3.3	194
16	Regulatory mechanisms of microRNAs involvement in cancer. Expert Opinion on Biological Therapy, 2007, 7, 1009-1019.	1.4	150
17	Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood, 2009, 113, 5568-5574.	0.6	129
18	WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15611-15616.	3.3	128

#	Article	IF	CITATIONS
19	Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology, 2005, 41, 995-1003.	3.6	113
20	L-Proline Induces a Mesenchymal-like Invasive Program in Embryonic Stem Cells by Remodeling H3K9 and H3K36 Methylation. Stem Cell Reports, 2013, 1, 307-321.	2.3	80
21	An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World Journal of Urology, 2019, 37, 507-514.	1.2	77
22	Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis, 2010, 31, 208-215.	1.3	68
23	Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis. Oncotarget, 2016, 7, 20636-20654.	0.8	66
24	Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer. Journal of Personalized Medicine, 2021, 11, 237.	1.1	58
25	Sarcoma Spheroids and Organoids—Promising Tools in the Era of Personalized Medicine. International Journal of Molecular Sciences, 2018, 19, 615.	1.8	57
26	Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers. Translational Research, 2017, 184, 108-117.	2.2	56
27	Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance. Oncotarget, 2017, 8, 18424-18434.	0.8	52
28	Protein Isoaspartate Methyltransferase Prevents Apoptosis Induced by Oxidative Stress in Endothelial Cells: Role of Bcl-XI Deamidation and Methylation. PLoS ONE, 2008, 3, e3258.	1.1	50
29	Effect of Reddening–Ripening on the Antioxidant Activity of Polyphenol Extracts from Cv. â€~Annurca' Apple Fruits. Journal of Agricultural and Food Chemistry, 2007, 55, 9977-9985.	2.4	47
30	microRNAs in the tumor microenvironment: solving the riddle for a better diagnostics. Expert Review of Molecular Diagnostics, 2014, 14, 565-574.	1.5	47
31	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy. Medicine (United States), 2015, 94, e1861.	0.4	43
32	Protein methylation as a marker of aspartate damage in glucose-6-phosphate dehydrogenase-deficient erythrocytes. FEBS Journal, 2002, 269, 2032-2039.	0.2	42
33	The role of a new class of long noncoding RNAs transcribed from ultraconserved regions in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 449-455.	3.3	37
34	Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs. Nature Communications, 2017, 8, 1801.	5.8	36
35	Modulation of the Pentose Phosphate Pathway Induces Endodermal Differentiation in Embryonic Stem Cells. PLoS ONE, 2012, 7, e29321.	1.1	33
36	Epigenetic alteration of microRNAs in DNMT3B-mutated patients of ICF syndrome. Epigenetics, 2010, 5, 427-443.	1.3	31

#	Article	IF	CITATIONS
37	Homocysteinylated Albumin Promotes Increased Monocyte-Endothelial Cell Adhesion and Up-Regulation of MCP1, Hsp60 and ADAM17. PLoS ONE, 2012, 7, e31388.	1.1	31
38	Plasma proteins containing damaged L-isoaspartyl residues are increased in uremia: Implications for mechanism. Kidney International, 2001, 59, 2299-2308.	2.6	26
39	New Cross-Talk Layer between Ultraconserved Non-Coding RNAs, MicroRNAs and Polycomb Protein YY1 in Bladder Cancer. Genes, 2016, 7, 127.	1.0	26
40	Direct detection of organophosphate compounds in water by a fluorescence-based biosensing device. Sensors and Actuators B: Chemical, 2018, 255, 3257-3266.	4.0	21
41	Metabolic consequences of hyperhomocysteinemia in uremia. American Journal of Kidney Diseases, 2001, 38, S85-S90.	2.1	20
42	An Ultraconserved Element Containing IncRNA Preserves Transcriptional Dynamics and Maintains ESC Self-Renewal. Stem Cell Reports, 2018, 10, 1102-1114.	2.3	17
43	The Fra-1/AP-1 Oncoprotein: From the "Undruggable―Transcription Factor to Therapeutic Targeting. Cancers, 2022, 14, 1480.	1.7	17
44	Oligonucleotide Analogues as Modulators of the Expression and Function of Noncoding RNAs (ncRNAs): Emerging Therapeutics Applications. Journal of Medicinal Chemistry, 2014, 57, 10220-10240.	2.9	13
45	Chemical modifications in the seed region of miRNAs 221/222 increase the silencing performances in gastrointestinal stromal tumor cells. European Journal of Medicinal Chemistry, 2016, 111, 15-25.	2.6	13
46	Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS). International Journal of Molecular Sciences, 2017, 18, 1146.	1.8	13
47	Peri-Prostatic Adipocyte-Released TGFβ Enhances Prostate Cancer Cell Motility by Upregulation of Connective Tissue Growth Factor. Biomedicines, 2021, 9, 1692.	1.4	13
48	Molecular characterization of G6PD deficiency in Southern Italy: heterogeneity, correlation genotype–phenotype and description of a new variant (G6PD Neapolis). British Journal of Haematology, 1997, 98, 41-46.	1.2	12
49	Determination of Picomolar Concentrations of Paraoxon in Human Urine by Fluorescence-Based Enzymatic Assay. Sensors, 2019, 19, 4852.	2.1	12
50	Subcellular Localization of uc.8+ as a Prognostic Biomarker in Bladder Cancer Tissue. Cancers, 2021, 13, 681.	1.7	12
51	Circulating tumor cells in bladder cancer: a new horizon of liquid biopsy for precision medicine. Journal of Basic and Clinical Physiology and Pharmacology, 2022, 33, 525-527.	0.7	12
52	Binding studies of antimicrobial peptides to Escherichia coli cells. Biochemical and Biophysical Research Communications, 2016, 478, 149-153.	1.0	7
53	Role of PA2G4P4 pseudogene in bladder cancer tumorigenesis. Biology, 2020, 9, 66.	1.3	5
54	Yin Yang I as an Epimodulator of miRNAs in the Metastatic Cascade. Critical Reviews in Oncogenesis, 2017, 22, 99-107.	0.2	5

#	Article	IF	CITATIONS
55	Perspective: Cancer Patient Management Challenges During the COVID-19 Pandemic. Frontiers in Oncology, 2020, 10, 1556.	1.3	4
56	Plasma proteins containing damaged l-isoaspartyl residues are increased in uremia: Implications for mechanism. Kidney International, 2001, 59, 2299.	2.6	3
57	High throughput microRNAs profiling in cancers. , 2007, , 309-321.		0
58	Effects of long non-coding RNAs on androgen signaling pathways in genitourinary malignancies. Molecular and Cellular Endocrinology, 2021, 526, 111197.	1.6	0
59	Circular RNAs: an emerging type of non-coding RNA and their potential implications in bladder cancer. Translational Cancer Research, 2018, 7, S758-S761.	0.4	0
60	Tumorigenesis-Related Long Noncoding RNAs and Their Targeting as Therapeutic Approach in Cancer. RNA Technologies, 2020, , 277-303.	0.2	0